Compare Stocks: SVNTQ, ONBI, PURR, and CURR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CURR Currenc Group	$3.16 +1.6%	$3.06	$1.29 ▼ $4.72	$238.26M	0.11	120,090 shs	57,638 shs
ONBI One Bio	$0.00	$0.00	$0.00 ▼ $0.02	N/A	6.47	N/A	N/A
PURR Hyperliquid Strategies	$6.60 -3.1%	$7.84	$3.01 ▼ $11.62	$983.69M	1.71	8.36 million shs	5.71 million shs
SVNTQ Savient Pharmaceuticals		$0.00	$0.00 ▼ $0.91	N/A	N/A	340,036 shs	N/A

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CURR Currenc Group	+1.61%	-2.17%	+2.60%	-28.51%	+107.89%
ONBI One Bio	0.00%	0.00%	0.00%	0.00%	+150.00%
PURR Hyperliquid Strategies	-3.08%	+0.30%	-12.58%	+5.60%	+659,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CURR Currenc Group	$3.16 +1.6%	$3.06	$1.29 ▼ $4.72	$238.26M	0.11	120,090 shs	57,638 shs
ONBI One Bio	$0.00	$0.00	$0.00 ▼ $0.02	N/A	6.47	N/A	N/A
PURR Hyperliquid Strategies	$6.60 -3.1%	$7.84	$3.01 ▼ $11.62	$983.69M	1.71	8.36 million shs	5.71 million shs
SVNTQ Savient Pharmaceuticals		$0.00	$0.00 ▼ $0.91	N/A	N/A	340,036 shs	N/A

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CURR Currenc Group	+1.61%	-2.17%	+2.60%	-28.51%	+107.89%
ONBI One Bio	0.00%	0.00%	0.00%	0.00%	+150.00%
PURR Hyperliquid Strategies	-3.08%	+0.30%	-12.58%	+5.60%	+659,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CURR Currenc Group	1.33	Sell	N/A	N/A
ONBI One Bio	0.00	N/A	N/A	N/A
PURR Hyperliquid Strategies	2.50	Moderate Buy	$12.72	92.68% Upside
SVNTQ Savient Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SVNTQ, ONBI, PURR, and CURR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2026	PURR Hyperliquid Strategies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$8.00 ➝ $18.40
6/24/2026	CURR Currenc Group	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Reduce
6/12/2026	PURR Hyperliquid Strategies	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$9.75
6/3/2026	PURR Hyperliquid Strategies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
5/20/2026	PURR Hyperliquid Strategies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (D)
5/20/2026	PURR Hyperliquid Strategies	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.45 ➝ $9.75
5/11/2026	PURR Hyperliquid Strategies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$6.00 ➝ $8.00

(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CURR Currenc Group	$37.81M	6.40	N/A	N/A	$0.24 per share	13.17
ONBI One Bio	N/A	N/A	N/A	N/A	N/A	N/A
PURR Hyperliquid Strategies	$1M	953.37	N/A	N/A	$1.52 per share	4.34
SVNTQ Savient Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CURR Currenc Group	-$18.43M	-$0.30	N/A	N/A	N/A	-48.74%	N/A	-18.15%	N/A
ONBI One Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PURR Hyperliquid Strategies	-$16.01M	-$7.37	N/A	N/A	N/A	N/A	-56.04%	-52.22%	N/A
SVNTQ Savient Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CURR Currenc Group	N/A	N/A	N/A	N/A	N/A
ONBI One Bio	N/A	N/A	N/A	N/A	N/A
PURR Hyperliquid Strategies	N/A	N/A	N/A	N/A	N/A
SVNTQ Savient Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CURR Currenc Group	0.25	1.12	1.12
ONBI One Bio	N/A	N/A	N/A
PURR Hyperliquid Strategies	N/A	18.23	18.22
SVNTQ Savient Pharmaceuticals	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CURR Currenc Group	56.01%
ONBI One Bio	N/A
PURR Hyperliquid Strategies	9.45%
SVNTQ Savient Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CURR Currenc Group	43.30%
ONBI One Bio	N/A
PURR Hyperliquid Strategies	8.48%
SVNTQ Savient Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CURR Currenc Group	2	76.61 million	43.44 million	N/A
ONBI One Bio	360	N/A	N/A	Not Optionable
PURR Hyperliquid Strategies	N/A	144.45 million	132.20 million	N/A
SVNTQ Savient Pharmaceuticals	N/A	N/A	N/A	Not Optionable

SVNTQ, ONBI, PURR, and CURR Headlines

Recent News About These Companies

Promising Market Potential and Efficacy of Syndax Pharmaceuticals’ Revumenib Justify Buy Rating

November 12, 2024 | markets.businessinsider.com

In defense of radioligand therapies, Novartis fired off patent lawsuits against Lilly and other rivals

November 4, 2024 | fiercepharma.comF

Incyte wins injunction to block launch of Sun Pharma's JAK inhibitor Leqselvi

November 4, 2024 | fiercepharma.comF

ETHealthworld Events

October 25, 2024 | health.economictimes.indiatimes.com

Pharmalittle: We’re reading about a probe of Pfizer and Lilly telehealth, pharma exec donations, and more

October 23, 2024 | statnews.comS

Stevanato Group to Report Third Quarter 2024 Financial Results on November 5, 2024

October 22, 2024 | businesswire.com

Genentech executive Fritz Bittenbender: Beware political soundbites

October 19, 2024 | statnews.comS

Qunova becomes first to achieve ‘chemical accuracy’ on commercial quantum computers with its hardware agnostic algorithm

October 14, 2024 | eurekalert.orgE

DeepIntent’s Blueprint for Healthcare Marketing Success

October 14, 2024 | fiercepharma.comF

Milestone Pharmaceuticals’ CARDAMYST: A Game Changer in PSVT Treatment with Significant Market Potential

October 14, 2024 | markets.businessinsider.com

Zantac’s Developer Settles Lawsuits Claiming Cancer Link

October 10, 2024 | nytimes.com

Dupixent takes pharma DTC top spot as Pfizer's COVID drug Paxlovid makes a comeback

October 7, 2024 | fiercepharma.comF

NutriQuest and Modulant Biosciences announce partnership to advance crucial PRRSv and swine disease research

September 28, 2024 | thepoultrysite.comT

Repair licenses Genevant's nucleic acid delivery tech for up to $107M per cardio product

September 28, 2024 | fiercebiotech.comF

Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer's Disease

September 26, 2024 | tmcnet.com

Truliant Consulting launches a white paper on Artificial Intelligence in Pharmacovigilance

September 19, 2024 | tmcnet.com

Pfizer, Sanofi, GSK among the winners of the 2024 Fierce Pharma Marketing Awards

September 12, 2024 | fiercepharma.comF

DCAT Debrief: Lonza's perspective on pharma's path forward with AI and drug development

April 16, 2024 | outsourcing-pharma.comO

FDA slams Jubilant Generics, Canada's Contract Pharmaceuticals with Form 483s

April 10, 2024 | fiercepharma.comF

Buy Rating Affirmed for Aquestive Therapeutics on Strong Phase 3 Results for Anaphylm™ with Raised Price Target

March 18, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SVNTQ, ONBI, PURR, and CURR Company Descriptions

Currenc Group NASDAQ:CURR

$3.16 +0.05 (+1.61%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$3.27 +0.11 (+3.61%)

As of 04:09 AM Eastern

Currenc Group, Inc. engages in operating a fintech banking platform. It operates through the following segments: Remittance Services, Sales of Airtime, and Other Services. The company is headquartered in Singapore.

One Bio OTCMKTS:ONBI

$0.0005 0.00 (0.00%)

As of 08/7/2026

ONE Bio Corp., an agritech company, together with its subsidiaries, utilizes green process manufacturing to produce raw chemicals and herbal extracts, natural supplements, and organic products. The company operates through two business units, Chemical and Herbal Extracts (CHE) and Organic Products (OP). The CHE business unit engages in the development, manufacture, and commercialization of bio-ecological products and over-the-counter products utilizing the extractions of tobacco leaves and various other plant materials. It produces chemical and herbal extracts for use in a range of health and wellness products, including chemical extracts comprising Solanesol and Coenzyme Q10; and herabal extracts, such as Resveratrol, 5-Hydroxytryptophan, Ganoderma Tea, and powdered and particulate fertilizers. This business unit distributes its products through independent third party distributors, universities, and hospital research centers to the bio-health industry and raw chemical intermediates industry in the People's Republic of China. The OP business unit manufactures various consumer and commercial use health and energy drinks, organic food products, and fertilizers primarily based on bamboo in the People's Republic of China. Its products include boiled bamboo shoot cans, boiled bamboo shoot cans with vacuum packing, boiled mixed vegetables, and boiled seasoned vegetables, as well as Kamameshi, a Japanese rice dish. This segment distributes its products directly to supermarket chains, hotels, hospitals, and restaurants, as well as through a network of independent third party distributors. ONE Bio Corp. exports its products to Japan, southeast Asia, Europe, and North America. The company was formerly known as ONE Holdings, Corp. and changed its name to ONE Bio Corp. in November 2009. ONE Bio Corp. was incorporated in 2000 and is headquartered in Aventura, Florida.

Hyperliquid Strategies NASDAQ:PURR

$6.60 -0.21 (-3.08%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$6.52 -0.08 (-1.26%)

As of 04:47 AM Eastern

Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. Hyperliquid Strategies Inc, formerly known as Sonnet BioTherapeutics Holdings Inc., is based in NEW YORK.

Savient Pharmaceuticals OTCMKTS:SVNTQ

Savient Pharmaceuticals, Inc. (Savient), incorporated in 1980, is a specialty biopharmaceutical company focused on commercializing KRYSTEXXA (pegloticase) in the United States and completing the development and seeking regulatory approval outside of the United States for KRYSTEXXA, particularly in the European Union. The Company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. In October 2013, the Company announced that it has elected to file voluntary petitions under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the Court). Effective January 10, 2014, Crealta Pharmaceuticals LLC, a majority owned unit of GTCR LLC acquired Savient Pharmaceuticals Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SVNTQ, ONBI, PURR, and CURR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SVNTQ, ONBI, PURR, and CURR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SVNTQ, ONBI, PURR, and CURR Company Descriptions

Currenc Group NASDAQ:CURR

One Bio OTCMKTS:ONBI

Hyperliquid Strategies NASDAQ:PURR

Savient Pharmaceuticals OTCMKTS:SVNTQ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SVNTQ, ONBI, PURR, and CURR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SVNTQ, ONBI, PURR, and CURR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SVNTQ, ONBI, PURR, and CURR Company Descriptions

Currenc Group NASDAQ:CURR

One Bio OTCMKTS:ONBI

Hyperliquid Strategies NASDAQ:PURR

Savient Pharmaceuticals OTCMKTS:SVNTQ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools